Ekaterina Alekseevna Karimova

Ekaterina Alekseevna Karimova

Auto-generated profile, based on publicly available information

Ekaterina Alekseevna Karimova

City Clinical Hospital No. 52, Moscow Healthcare Department

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2019 in Russian journal of hematology and transfusiology
Verified
Journal Article
Open access
PDF file
SSS. V. Semochkin
S. V. Semochkin
EZE. I. Zhelnova
E. I. Zhelnova
EME. N. Misyurina
E. N. Misyurina
DMD. S. Maryin
D. S. Maryin
AUA. I. Ushakova
A. I. Ushakova
MLM. A. Lysenko
M. A. Lysenko
Introduction. Kidney damage at the onset of multiple myeloma (MM) is observed in 20–40 % of patients, which requires renal replacement therapy in 2–4 % of cases. Deterioration in kidney function is associated with frequent complications and a decline in the quality of life, as well as carries a high risk of early death.Aim. To analyze the treatment of patients first diagnosed with MM, complicated by severe and dialysis-dependent renal failure.Materials and methods. 62 MM patients with a glomerular filtration rate of 500 mg/l and the selective nature of proteinuria. Diagnosed AL-amyloidosis served as the exclusion criterion. Depending on the need for haemodialysis, patients were divided into two groups: (I) those not requiring it (n = 16) and (II) dialysis-dependent patients (n = 46).Results. The induction therapy included the following bortezomib-containing regimens: VCD — 41 (66.1 %), PAD — 2 (3.2 %), VD — 12 (19.4 %) and VMP — 7 (11.3 %). High-dose consolidation along with autologous hematopoietic stem cell transplantation was performed in 10 patients (16.1 %). The overall rate of anti-myeloma response in the groups came to 64.3 % (I) and 85.3 % (II) (p = 0.047), including complete and strong complete remissions in 14.3 % (I) and 14.7 % (II) of cases. The renal response was achieved by 57.2 % and 23.5 % (p = 0.032) of patients from the first and second groups, respectively. With a median follow-up of 32.1 months, throughout the entire cohort the median of progression-free survival (PFS) amounted to 14.5 months, with a 3-year PFS of 27.4 ± 6.6 %; whereas the median of overall survival (OS) came to 33.6 months, with a 3-year OS of 41.5 ± 7.7 %. There are no differences between the compared groups in terms of the survival rates. In the examined patients (n = 48), the achievement of any renal response was associated with an improvement in the 3-year PFS — 61.1 ± 11.5 % versus 17.7 ± 7.7 % (p = 0.045) — and 3-year OS — 72,2 ± 10.6 % versus 38.1 ± 10.4 % (p= 0.069). The time elapsed between the first haemodialysis procedure and the onset of anti-myeloma chemotherapy served as the predictor value of the renal response. In the group of patients who achieved a renal response, the average time came to 8.6 (95 % confidence interval of 3.5–13.7) days, as compared to 42.5 (12.6–72.5) days for patients without a renal response (p = 0.045).Conclusion. The use of bortezomib-based regimens provides a high frequency of antitumour responses with a probability of stopping dialysis in 23.5 % of dialysis-dependent patients. Possible reasons for the low frequency of renal response include the late diagnosis of MM as a cause of kidney damage, as well as the lack of access to new anti-myeloma drugs if the induction therapy needs to be changed.

10 December 2025 in Oncohematology
Verified
Journal Article
Open access
PDF file
EMElena N. Misyurina
Elena N. Misyurina
EZE. N. Zotina
E. N. Zotina
SGS. M. Gadzhieva
S. M. Gadzhieva
NCNatalia Chernova
Natalia Chernova
EKE. A. Karimova
E. A. Karimova
TST. A. Semina
T. A. Semina
Background. Multiple myeloma (MM) is the second most common oncohematological disease among malignant tumors of the hematopoietic and lymphoid tissues. According to epidemiological data, MM accounts for approximately 10–12 % of all hematological malignancies. An analysis of the main clinical parameters and treatment outcomes was conducted in patients with MM included in the registry of the Moscow Clinical Research Center “Hospital 52” in 2022–2025. Aim. To evaluate the clinical and hematological profile of MM patients, as well as to analyze the effectiveness of first-line antitumor therapy, including standard treatment regimens and high-dose chemotherapy programs followed by autologous hematopoietic stem cell transplantation. Materials and methods. The observational retrospective study included 325 patients with newly diagnosed MM: 147 (45.2 %) men, 178 (54.8 %) women. The median age at diagnosis was 67 (22–92) years. The number of patients aged 65 years and older was 194 (59.7 %). Antitumor therapy was carried out according to current clinical guidelines. In the first line of therapy, bortezomib was most often used, in the second – lenalidomide and monoclonal antibodies, in the third – monoclonal antibodies. Results. According to the International Staging System, 62.2 % of patients had stage III disease. Myeloma nephropathy was detected in 28.9 % of patients, with 20.3 % requiring programmed dialysis. Autologous hematopoietic stem cell transplantation was performed in 30.8 % of patients. Response to induction therapy: complete remission – 8.0 %; very good partial remission – 27.7 %; partial remission – 24.6 %. The best response rates were achieved with the use of monoclonal antibodies (66.6 % – complete remission + very good partial remission). With a median follow-up of 12.6 months, 1-year overall survival was 83.9 % (95 % confidence interval 82.3–85.4), 1-year progression-free survival was 75.8 % (95 % confidence interval 73.9–77.6). Conclusion. Using registry data allows us to characterize the MM patient population, evaluate the effectiveness of patient treatment, plan the work of the hematology center, forecast the funds required for the purchase of medications, and improve the organizational aspects of the hematology service in a multidisciplinary institution.

14 January 2024 in Oncohematology
Verified
Journal Article
Open access
PDF file
OKO. L. Kochneva
O. L. Kochneva
EBE. A. Baryakh
E. A. Baryakh
EME. N. Misyurina
E. N. Misyurina
EZE. I. Zhelnova
E. I. Zhelnova
KYK. V. Yatskov
K. V. Yatskov
ЮПЮ. Ю. Поляков
Ю. Ю. Поляков
Background. At the end of 2019, a new coronavirus infection caused by the SARS-CoV-2 virus was registered. In March 2020, the first cases of COVID-19 were detected in Moscow. Patients with chronic lymphocytic leukemia, characterized by profound immune dysfunction, have risk factors for severe viral disease.Aim. To identify risk factors for hospital mortality and severe course of COVID-19, as well as to optimize therapeutic and preventive measures.Materials and methods. The analysis included 238 patients (142 (59 %) men and 96 (41 %) women) with chronic lymphocytic leukemia and COVID-19 with a median age of 66 (37-90) years, who were hospitalized at City Clinical Hospital No. 52 (Moscow) between April 2020 and April 2023. To compare hospital mortality and severity of COVID-19, patients were divided into 2 groups depending on the hospitalization period: 2020-2021 and 2022-2023, which correlates with the prevalence of some SARS-CoV-2 variants from December 2021 and changes in Moscow epidemiological situation.Results. Overall hospital mortality rate in 2020-2021 was 25 % (n = 45). Age over 73 years was a significant unfavorable factor in men. Cardiovascular diseases increase the risk of death by 2.3 times. Patients with a Charlson Comorbidity Index of 6 or more have a 2.2 times greater risk of death. A history of 1 or more lines of immunochemotherapy increased the risk of hospital mortality by 1.5 times. Relapse/progression of the disease were factors of unfavorable prognosis for patient survival. Binet stage C also showed a significant unfavorable prognosis. When studying all cases of death (n = 51), complications such as myelotoxic agranulocytosis, secondary bacterial complications and severe interstitial pulmonary damage 75 % were identified.Conclusion. Coronavirus infection caused by SARS-CoV-2 represents an infectious threat among patients with chronic lymphocytic leukemia and may affect the regimen and tactics of antitumor therapy. The use of a full range of preventive measures, vaccination and pre-exposure prophylaxis in this cohort of patients is of great importance.

14 January 2024 in Oncohematology
Verified
Journal Article
Open access
PDF file
DGD. E. Gagloeva
D. E. Gagloeva
EME. N. Misyurina
E. N. Misyurina
TTT. N. Tolstykh
T. N. Tolstykh
EBE. A. Baryakh
E. A. Baryakh
KYK. V. Yatskov
K. V. Yatskov
EZE. I. Zhelnova
E. I. Zhelnova
Background. Acute myeloid leukemia (AML) is a highly aggressive oncological disease of the blood and bone marrow, requiring extremely toxic chemotherapy and massive supportive treatment to achieve stable remission. Currently, there is no work to provide medical care to these patients with a high risk of coronavirus infection. This paper presents treatment results of a large AML patient cohort during the COVID-19 pandemic.Aim. To assess the clinical features of coronavirus infection in AML patients.Materials and methods. A retrospective cohort study included patients hospitalized at City Clinical Hospital No. 52 (Moscow) between March 2020 and March 2022. Study inclusion criteria: 1) AML diagnosed within the last 3 years before the development of the COVID-19 pandemic; 2) age over 18 years; 3) laboratory confirmed SARS-CoV-2. AML status (newly diagnosed AML, relapse/refractory disease, remission), age, gender, comorbidity index, previous AML therapy and its outcomes were also assessed.Results. Among 218 patients with acute leukemia, 60 (27.5 %) patients had acute lymphoid leukemia, 158 (72.5 %) had AML. Patients with acute promyelocytic leukemia were allocated to a separate group - 20 (9 %) patients. The statistical data of the remaining 138 (63.5 %) patients with AML, their survival and mortality rates were assessed, and the main prognostic factors influencing the mortality and severity of coronavirus infection were identified. Also, our own results were compared with world statistics.Conclusion. Coronavirus infection in AML patients significantly worsens the prognosis. The main factors influencing the severity of coronavirus infection and survival and mortality rates are age, somatic status of patients due to the presence of concomitant chronic diseases, the development of deep hypoplasia of hematopoiesis, and the active AML status (disease onset or resistant course).

14 January 2024 in Oncohematology
Verified
Journal Article
Open access
PDF file
EME. N. Misyurina
E. N. Misyurina
EBE. A. Baryakh
E. A. Baryakh
NFN. F. Frolova
N. F. Frolova
OKO. N. Kotenko
O. N. Kotenko
ZMZ. Yu. Mutovina
Z. Yu. Mutovina
ЮПЮ. Ю. Поляков
Ю. Ю. Поляков
In December 2019, cases of severe respiratory infection were reported in Wuhan, China. The disease was caused by a new, previously undescribed coronavirus, structurally similar to the then known SARS-CoV virus. The World Health Organization has named the new virus SARS-CoV-2 and the disease it causes COVID-19. The problem of COVID-19 is exacerbated by the rapid spread of the SARS-CoV-2 virus and the development of life-threatening complications, the main of which is pneumonia. Due to the severity of the condition, from 5 to 10 % of patients are treated in intensive care units.SARS-CoV-2 initially attacks the respiratory system and causes symptoms such as fever, vomiting, headache, dizziness, general weakness, and diarrhea. Then these symptoms intensify in different directions, and the disease can often lead to death.Initially, only a few methods of symptomatic treatment were available and clinical trials of drugs that had previously shown their effectiveness against infection with the MERS-CoV and SARS-CoV viruses began. Temporary recommendations have appeared suggesting the use of some drugs both in monotherapy and in combination.In patients with hematologic malignancies, the immune response to the SARS-CoV-2 coronavirus is significantly reduced, which explains the high mortality rate (up to 38 %) of these patients hospitalized for SARS-CoV-2 infection. Recently, antiviral drugs and monoclonal antibodies have become available for pre- or post-exposure prophylaxis, as well as for early treatment of COVID-19. These treatments should be offered to patients at high risk of severe COVID-19 and to those who have not responded to vaccination. However, as changes in the genetic structure of the virus accumulate, some treatments may lose their clinical effectiveness against new variants.The combination of hematological malignancies and new coronavirus infection causes a more severe course of COVID-19 compared to the population and high mortality. Factors for an unfavorable prognosis for new coronavirus infection in patients with hematological malignancies include age over 60 years, a high comorbidity index, diagnoses such as acute leukemia, especially acute myeloid leukemia and myelodysplastic syndrome, disease status (relapse, progression, as well as newly diagnosed acute leukemia), severe COVID-19, agranulocytosis (myelotoxic or tumor).

1 April 2025 in Clinical oncohematology
Verified
Journal Article
Open access
PDF file
EKEkaterina Alekseevna Karimova
Ekaterina Alekseevna Karimova
EZE. I. Zhelnova
E. I. Zhelnova
EBE. A. Baryakh
E. A. Baryakh
EGE. Yu. Grishina
E. Yu. Grishina
EZE. N. Zotina
E. N. Zotina
EME. N. Misyurina
E. N. Misyurina
BACKGROUND. Renal failures, among them dialysis-dependent kidney disease, are common complications of multiple myeloma (ММ). Hemodialysis (HD) independence is achieved in only 20 % of standard induction therapy recipients. The survival of program HD patients remains unsatisfactory. Autologous hematopoietic stem cell transplantation (auto-HSCT) is usually planned and performed in young MM patients. However, the program HD patients are often excluded from the high-dose chemotherapy protocols with subsequent auto-HSCT due to the therapy associated toxicity risk. AIM. To assess the efficacy and safety of auto-HSCT in MM complicated by dialysis-dependent renal failure. MATERIALS & METHODS. In the period from 2015 to 2022, 14 program HD patients (8 men and 6 women) received auto-HSCT at the City Clinical Hospital No. 52. The median age was 53 years (range 43–66 years). In two patients, tandem transplantation was performed. Melphalan 140 mg/m2 (n = 10) was administered for pre-transplant conditioning. In 4 patients, bendamustine 200 mg/m2 was added to melphalan in the conditioning regimen. The median transfused СD34+ cell count was 3.61 × 106/kg (range 1.34–9.69 × 106/kg). By the time of completing bortezomib and/or lenalidomide induction therapy, complete remission (CR) was achieved in 5 patients, other 5 patients showed very good partial remission (VGPR), and in 4 patients partial remission (PR) was registered. RESULTS. As reported by the control follow-up on Day +100 after auto-HSCT, all patients demonstrated further deepening of antitumor response. By this time, CR in 11 (79 %) patients and VGPR in 2 (14 %) patients were registered, whereas 1 (7 %) patient maintained PR. Renal response and HD independence were achieved in 8 (57 %) out of 14 patients enrolled in the trial. In the total group (n = 14), the 3-year event-free survival was 50 % and overall survival was 78 %. CONCLUSION. Dialysis-dependent renal failure in MM patients is no contraindication to auto-HSCT. The latter will improve chemotherapy outcomes and make it possible to achieve renal response and HD independence.